From D.A.R.E. to the Cannabis Debate: How the Conversation Changed

A school drug-prevention lesson may be part of your memory of the 1990s: a visiting officer, a classroom discussion or a handout to take home. Years later, the conversation can sound very different. Cannabis appears in debates about criminal law, prescription medicines, retail products and personal choice.

School prevention, drug law and medical research have different purposes. A useful way through today's debate is to ask which question a claim is answering.

Policy and health sources reviewed October 17, 2026.

What happened to the classroom lessons?

D.A.R.E. stands for Drug Abuse Resistance Education. The program began in Los Angeles in 1983, with lessons intended to help young people resist substance use and peer pressure.

The National Institute of Justice's evaluation profile of the original 1983–2009 curriculum rates that program Ineffective on the outcomes it reviewed. The profile describes studies that did not find significant differences in the specified substance-use outcomes between the groups being compared.

The profile explicitly excludes the current curriculum. Its rating concerns the earlier lessons and the outcomes in the studies reviewed. A person's memory of a classroom lesson remains a different kind of account from an evaluation of a program.

Public opinion has changed, too. Gallup's trend series reports 25% support for legalizing marijuana in August 1995 and 64% in October 2025 among U.S. adults. These are national adult survey results, not a finding about all millennials or a study of D.A.R.E.'s effects.

A legal change needs a place and a date

“Legal” can mean several things in a cannabis headline. A state medical program, adult-use possession rules and federal drug controls have different requirements. An old count of states won't tell you which rules apply to a particular activity today.

Federal policy has also changed. An April 28, 2026 final rule, effective that date, moved FDA-approved products containing marijuana and marijuana regulated under a state medical marijuana license into Schedule III. Under that rule, marijuana outside the specified categories remains in Schedule I. The DEA's regulatory-actions page separately describes proceedings concerning broader rescheduling.

This isn't blanket federal legalization. The rule retains federal controls, and state permission does not settle every federal requirement. For a specific situation, check the current official rules for the jurisdiction and get qualified legal advice when needed. This article describes the policy discussion; it cannot establish personal permission to possess, buy, sell or travel with a product.

Comparisons with other countries need the same care. The country, activity, age restrictions and date all matter. A headline about one country's policy is a poor guide to what someone may do somewhere else.

A medicine and a wellness product need separate evidence

Cannabis contains different compounds, including THC and CBD. They aren't interchangeable, and neither name identifies a single standardized consumer product.

The FDA identifies specific approved prescription medicines: the cannabis-derived product Epidiolex and the synthetic cannabis-related products Marinol, Syndros and Cesamet. Their approvals concern particular products and uses. They don't approve every cannabis product, dispensary preparation or CBD oil sold with a wellness claim.

The FDA's consumer guidance on CBD describes concerns including liver injury, interactions with medicines and sedation. Calling something natural does not establish its safety. A gummy, lotion or oil needs evidence about the actual preparation and the claim being made.

Don't replace prescribed treatment on the strength of an advertisement or a friend's experience. A clinician can consider the condition, other medicines and the product involved. A personal account may describe something important to that person, but it cannot tell every reader what will work for them.

Pain, anxiety and sleep are different research questions

The evidence doesn't support treating these concerns as one general promise of better wellness. The CDC's pain overview describes limited evidence for most acute or chronic pain, while noting research suggesting help for some neuropathic pain. That doesn't establish cannabis as a general pain cure or a replacement for opioid treatment.

For anxiety, the National Center for Complementary and Integrative Health discusses small, preliminary studies. The CDC also describes anxiety and paranoia after cannabis use. Those findings don't justify recommending consumer cannabis or CBD as an established treatment for anxiety or depression.

Sleep research needs similar distinctions. Feeling sleepy, reporting better sleep while another symptom improves and treating a sleep disorder aren't the same outcome. NCCIH's cannabis review says it is uncertain whether sleep improvements reflect a direct effect or relief of other symptoms, and whether cannabinoids help people without another illness sleep better.

Results apply to the formulation and patient group studied. An oil or gummy with different ingredients needs its own evidence.

The alcohol comparison leaves some questions unanswered

Cannabis has risks that belong in any comparison with alcohol. It can cause impairment, and cannabis use disorder can occur.

The CDC's driving guidance describes effects on reaction time, coordination and decision-making. Combining cannabis and alcohol can increase impairment. A claim that a product avoids hangovers doesn't establish that someone is safe to drive or that regular use has no health consequences.

Research on psychedelics has its own questions

Psilocybin and MDMA also appear in discussions of mental-health research. Their research programs and legal status need to be examined separately from cannabis.

The FDA's psychedelic-drug resources describe clinical development and investigation. Permission to run a study or a designation intended to support development is not marketing approval. The VA's MDMA information identifies it as an unapproved treatment.

Research headlines can be worth following without predicting that these substances will repeat cannabis's political or commercial history. The preparation, condition being studied, trial design and regulatory decision all need their own evidence.

Different memories can lead to a better discussion

Millennials don't have one shared position on cannabis. Someone may approach the subject through a school memory, a family experience, treatment access or a concern about criminal penalties. Those starting points can explain a disagreement without settling the facts behind it.

When a new claim comes up, ask what it is actually about. Is it a policy change, a particular medicine, a study result or a product being sold? Check the date and follow the source. There is room to question what we were taught at school and still expect careful evidence from the claims we hear as adults.